Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST Harbouring KIT Exon 9 Mutations By Ogkologos - March 10, 2026 333 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an international retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR This Bar of Soap with a Lump Will Help You Remember... May 31, 2019 EMA Recommends Extension of Indications for Niraparib September 29, 2020 Targeting FGFR1 in Patients with Tumour-Induced Osteomalacia September 16, 2020 FDA Approves Azacitidine for Newly Diagnosed Juvenile Myelomonocytic Leukaemia June 2, 2022 Load more HOT NEWS News digest – calorie guidelines, reduced lung cancer referrals and COVID-19’s... Bride’s Escorted Down Aisle By Dad Of Organ Donor Who Saved... Greater Severity of Adverse Events in Women Across Multiple Anticancer Treatment... The Late Alex Trebek’s Wardrobe Is Being Given to Homeless Men...
